Inhibition of JAK2 signaling by TG101209 enhances radiotherapy in lung cancer models

Journal of Thoracic Oncology

Volumn 6, Issue 4, 2011, Pages 699-706

  Sun, Yunguang ^a   Moretti, Luigi ^a   Giacalone, Nicholas J ^a   Schleicher, Stephen ^a   Speirs, Christina K ^a   Carbone, David P ^a   Lu, Bo ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

JAK2; Non small cell lung carcinoma; Radiation; Survivin

Indexed keywords

JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; N TERT BUTYL 3 [5 METHYL 2 [4 (4 METHYL 1 PIPERAZINYL)PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAS PROTEIN; SURVIVIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; RADIOSENSITIZATION;

EID: 79953025630     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31820d9d11     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer JClin 2009;59:225-249.
2. Altieri DC Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003;3:46-54. (Pubitemid 37328886)
3. Chakravarti A, Zhai GG, Zhang M, et al. Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene 2004;23:7494-7506. (Pubitemid 39389691)
4. Kami K, Doi R, Koizumi M, et al. Downregulation of survivin by siRNA diminishes radioresistance of pancreatic cancer cells. Surgery 2005;138: 299-305. (Pubitemid 41253814)
5. KapplerM, Bache M, Bartel F, et al. Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53. Cancer Gene Ther 2004;11: 186-193. (Pubitemid 38280521)
6. Lu B, Mu Y, Cao C, et al. Survivin as a therapeutic target for radiation sensitization in lung cancer. Cancer Res 2004;64:2840-2845. (Pubitemid 38500623)
7. Lu B, Gonzalez A, Massion PP, et al. Nuclear survivin as a biomarker for non-small-cell lung cancer. Br J Cancer 2004;91:537-540. (Pubitemid 39093575)
8. Shinohara ET, Gonzalez A, Massion PP, et al. Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma. Cancer 2005;103:1685-1692. (Pubitemid 40490030)
9. Aoki Y, Feldman GM, Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lym-phoma. Blood 2003;101:1535-1542. (Pubitemid 36182531)
10. Gritsko T, Williams A, Turkson J, et al. Persistent activation of Stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancercells. Clin Cancer Res 2006;12:11-19. (Pubitemid 43166170)
11. Kanda N, Seno H, Konda Y, et al. STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene 2004;23:4921-4929. (Pubitemid 38932164)
12. Nam S, Buettner R, Turkson J, et al. Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc Natl Acad Sci USA 2005;102:5998-6003. (Pubitemid 40594244)
13. Diaz N, Minton S, Cox C, et al. Activation of Stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated Src and survivin expression. Clin Cancer Res 2006;12:20-28. (Pubitemid 43166171)
14. Schlette EJ, Medeiros LJ, Goy A, et al. Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol 2004; 22:1682-1688. (Pubitemid 41079807)
15. Kim KW, Mutter RW, Cao C, et al. Inhibition of signal transducer and activator of transcription 3 activity results in down-regulation of survivin following irradiation. Mol Cancer Ther 2006;5:2659-2665. (Pubitemid 44848992)
16. Zhong Z, Wen Z, Darnell J Jr. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994;264:95-98. (Pubitemid 24144493)
17. Darnell JE Jr. STATs and gene regulation. Science 1997;277:1630-1635. (Pubitemid 27446219)
18. Sasse J, Hemmann U, Schwartz C, et al. Mutational analysis of acute-phase response factor/Stat3 activation and dimerization. Mol Cell Biol 1997;17:4677-4686. (Pubitemid 27318143)
19. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002;8:945-954. (Pubitemid 35177340)
20. Yu H, Jove R. The STATs of cancer\new molecular targets come of age. Nat Rev Cancer 2004;4:97-105. (Pubitemid 38198738)
21. Dang TP, Gazdar AF, Virmani AK, et al. Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. JNatl Cancer Inst 2000;92:1355-1357. (Pubitemid 30660597)
22. Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998;58:5315-5320. (Pubitemid 28551107)
23. Rodel C, Haas J, Groth A, et al. Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosen-sitivities: survivin as a radioresistance factor. Int J Radiat Oncol Biol Phys 2003;55:1341-1347. (Pubitemid 36338302)
24. Tanaka K, Iwamoto S, Gon G, et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000;6:127-134. (Pubitemid 30064984)
25. Satoh K, Kaneko K, Hirota M, et al. Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer 2001;92:271-278. (Pubitemid 32664432)
26. Haura EB, Zheng Z, Song L, et al. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res 2005;11:8288-8294. (Pubitemid 41746939)
27. Song L, Turkson J, Karras JG, et al. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 2003;22:4150-4165. (Pubitemid 36876236)
28. Mesri M, Wall NR, Li J, et al. Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest 2001;108:981-990. (Pubitemid 32946072)
29. Wang Y, Fiskus W, Chong DG, et al. Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloprolifera-tive neoplastic cells. Blood 2009;114:5024-5033.
30. Ma AC, Fan A, Ward AC, et al. A novel zebrafish jak2a(V581F) model shared features of human JAK2(V617F) polycythemia vera. Exp Hema-tol 2009;37:1379.e4-1386.e4.
31. Libani IV, Guy EC, Melchiori L, et al. Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalasse-mia. Blood 2008;112:875-885.
32. Pardanani A, Hood J, Lasho T, et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative dis-order-associated JAK2V617F and MPLW515L/K mutations. Leukemia 2007;21:1658-1668. (Pubitemid 47086756)
33. Sirzen F, Zhivotovsky B, Nilsson A, et al. Spontaneous and radiation-induced apoptosis in lung carcinoma cells with different intrinsic radi-osensitivities. Anticancer Res 1998;18:695-699. (Pubitemid 28239582)
34. Sos ML, Fischer S, Ullrich R, et al. Identifying genotype-dependent efficacy of single and combined PI3K-and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci USA 2009;106:18351-18356.
35. Washburn KB, Neary JT. P2 purinergic receptors signal to STAT3 in astrocytes: difference in STAT3 responses to P2Y and P2X receptor activation. Neuroscience 2006;142:411-423. (Pubitemid 44415340)
36. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoSMed 2005;2:e73.
37. Yazlovitskaya EM, Linkous AG, Thotala DK, et al. Cytosolic phospho-lipase A2 regulates viability of irradiated vascular endothelium. Cell Death Differ 2008;15:1641-1653.
38. Fukuda S, Singh P, Moh A, et al. Survivin mediates aberrant hemato-poietic progenitor cell proliferation and acute leukemia in mice induced by internal tandem duplication of Flt3. Blood 2009;114:394-403.
39. Vargiolu M, Fusco D, Kurelac I, et al. The tyrosine kinase receptor RET interacts in vivo with aryl hydrocarbon receptor-interacting protein to alter survivin availability. J Clin Endocrinol Metab 2009;94:2571-2578.